Synergistic Induction of Erlotinib-Mediated Apoptosis by Resveratrol in Human Non-Small-Cell Lung Cancer Cells by Down-Regulating Survivin and Up-Regulating PUMA

Background/Aim: Treatment of human non-small-cell lung cancer (NSCLC) often involves uses of multiple therapeutic strategies with different mechanisms of action. Here we found that resveratrol (RV) enhanced the anti-tumor effects of epidermal growth factor receptor (EGFR) inhibitor erlotinib in NSCL...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cellular Physiology and Biochemistry 2015-01, Vol.35 (6), p.2255-2271
Hauptverfasser:	Nie, Peipei, Hu, Weicheng, Zhang, Tao, Yang, Yiju, Hou, Benxin, Zou, Zhengzhi
Format:	Artikel
Sprache:	eng
Schlagworte:	Apoptosis Apoptosis - drug effects Apoptosis Regulatory Proteins - metabolism Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - metabolism Caspase 3 - metabolism Cell Line, Tumor Down-Regulation - drug effects Drug Synergism Drug therapy Erlotinib Erlotinib Hydrochloride - pharmacology Health aspects Humans Inhibitor of Apoptosis Proteins - metabolism Lung cancer, Small cell Lung Neoplasms - drug therapy Lung Neoplasms - metabolism Myeloid Cell Leukemia Sequence 1 Protein - metabolism NSCLC Original Paper Proto-Oncogene Proteins - metabolism Proto-Oncogene Proteins c-akt - metabolism PUMA Reactive Oxygen Species - metabolism Resveratrol Ribosomal Protein S6 Kinases - metabolism Signal Transduction - drug effects Stilbenes - pharmacology Survivin Synergistic Testing TOR Serine-Threonine Kinases - metabolism Tumor Suppressor Protein p53 Up-Regulation - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!